Pfizer Inc.-backed biopharma company Imara Inc. filed initial public offering documents (https://www.sec.gov/Archives/edgar/data/1672619/000119312520038557/d842128ds1.htm) late Friday with the Securities and Exchange Commission, planning to list on the Nasdaq Global Market under the ticker symbol "IMRA." According to the documents, Imara plans to raise $86.3 million, and Morgan Stanley, Citigroup and SVB Leerink are underwriting the issue. "We are a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, known as hemoglobinopathies," the company wrote in the prospectus. The company has not booked revenue in 2019 and reported a net loss of $23.5 million, widening from the previous year's $11.3 million loss. The company has $28.9 million in cash and equivalents as of the end of December. Pfizer (PFE) owns a stake in the company through its Pfizer Ventures LLC investment arm.
-Max A. Cherney; 415-439-6400; AskNewswires@dowjones.com
Any recommendation, opinion or advice regarding securities or markets contained in such material does not reflect the views of TD Ameritrade, and TD Ameritrade does not verify any information included in such material.